Rebecsinib (investigational agent for high-risk MF / sAML)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-06-04 — A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis: Early-phase dose-finding trial evaluating safety and optimal dosing of rebecsinib (IV on Days 1, 4, 8, 11 of each 28-day cycle, up to 6 cycles) in relapsed/refractory secondary AML or high-risk myelofibrosis (trial-early). (novelty: 3)
Open questions
Related
Contributing findings
A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
04-jun-2026
novelty 3
per-area 3
introduces